These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19245345)

  • 1. The glatiramoid class of immunomodulator drugs.
    Varkony H; Weinstein V; Klinger E; Sterling J; Cooperman H; Komlosh T; Ladkani D; Schwartz R
    Expert Opin Pharmacother; 2009 Mar; 10(4):657-68. PubMed ID: 19245345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update.
    Johnson KP
    Expert Opin Drug Metab Toxicol; 2010 May; 6(5):643-60. PubMed ID: 20397968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative long-term preclinical safety evaluation of two glatiramoid compounds (glatiramer Acetate, Copaxone(R), and TV-5010, protiramer) in rats and monkeys.
    Ramot Y; Rosenstock M; Klinger E; Bursztyn D; Nyska A; Shinar DM
    Toxicol Pathol; 2012; 40(1):40-54. PubMed ID: 22083585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glatiramer acetate for the treatment of multiple sclerosis.
    Wolinsky JS
    Expert Opin Pharmacother; 2004 Apr; 5(4):875-91. PubMed ID: 15102570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
    Makhani N; Ngan BY; Kamath BM; Yeh EA
    Neurology; 2013 Aug; 81(9):850-2. PubMed ID: 23884038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis.
    De Stefano N; Filippi M; Confavreux C; Vermersch P; Simu M; Sindic C; Hupperts R; Bajenaru O; Edan G; Grimaldi L; Marginean I; Medaer R; Orefice G; Pascu I; Pelletier J; Sanders E; Scarpini E; Mancardi GL
    Mult Scler; 2009 Feb; 15(2):238-43. PubMed ID: 18987103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A comparative evaluation of immunomodulating drugs in the treatment of remitting multiple sclerosis].
    Zvartau ME; Kaon K; Lisak RF; Kan OA; Skoromets AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(7):66-71. PubMed ID: 15347038
    [No Abstract]   [Full Text] [Related]  

  • 12. Glatiramer acetate in multiple sclerosis: a review.
    Ruggieri M; Avolio C; Livrea P; Trojano M
    CNS Drug Rev; 2007; 13(2):178-91. PubMed ID: 17627671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.
    Johnson KP
    Expert Rev Neurother; 2012 Apr; 12(4):371-84. PubMed ID: 22449210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS
    Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glatiramer acetate (Copaxone) influence on different stages of multiple sclerosis pathogenesis].
    Shmidt TE; Zhuchenko TD; Iakhno NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):79-82. PubMed ID: 12938640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.
    Bell C; Anderson J; Ganguly T; Prescott J; Capila I; Lansing JC; Sachleben R; Iyer M; Fier I; Roach J; Storey K; Miller P; Hall S; Kantor D; Greenberg BM; Nair K; Glajch J
    J Pharm Pract; 2018 Oct; 31(5):481-488. PubMed ID: 28847230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune hyperthyroidism in multiple sclerosis under treatment with glatiramer acetate--a case report.
    Heesen C; Gbadamosi J; Schoser BG; Pöhlau D
    Eur J Neurol; 2001 Mar; 8(2):199. PubMed ID: 11285002
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.
    Galetta SL; Markowitz C; Lee AG
    Arch Intern Med; 2002 Oct; 162(19):2161-9. PubMed ID: 12390057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.